SCYX News and Press, SCYNEXIS Inc. From 04/26/22

JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price of $3.00 p...

Gainers: Vallon Pharmaceuticals (VLON) +80%. Blueknight Energy Partners (BKEP) +38%. Moving iMage Technologies (MITQ) +37%. RISE Education Cayman (REDU) +15%. Sky Harbour Group (SKYH) +14%. GWG Holdings (GWGH) +14%. Evelo Biosciences (EVLO) +13%. Chindata Group Holdings (CD) +13%. Shattuck La...

Gainers: Vallon Pharmaceuticals (VLON) +84%. Shattuck Labs (STTK) +12%. Establishment Labs (ESTA) +11%. INVO Bioscience (INVO) +5%. Novan (NOVN) +5%. Losers: Babylon Holdings (BBLN) -41%. SCYNEXIS (SCYX) -25%. Clarus Therapeutics (CRXT) -16%. HCA H...

SCYNEXIS (NASDAQ:SCYX) slumps 17.2% premarket after it priced its earlier announced underwritten public offering of 3.33M shares of its common stock, prefunded warrants to purchase 11.67M shares of common stock and warrants to purchase an aggregate of 15M shares ...

Scynexis (NASDAQ:SCYX) said interim data from two ongoing phase 3 studies of oral ibrexafungerp showed improvement in ~61% of patients with fungal infection. Data from 131 patients — 113 patients in the phase 3 trial called FURI and 18 patients from the phase 3 study, dubbed CARES...

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $3.00 per share and acc...

Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting. Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafunger...

Gainers: Pyxis Oncology (PYXS) +14%. SVB Financial Group (SIVB) +11%. Adaptive Biotechnologies Corporation (ADPT) +6%. Taboola  (TBLA) +6%. UFP Industries(UFPI) +5%. Losers: SCYNEXIS (SCYX) -21%. Corsair Gaming (CRSR) -13%. LifeMD (LFMD) -9%. Clarus Therapeutics ...

Scynexis (NASDAQ:SCYX) launched Thursday after market close its direct offering of shares and warrants. The offering is to include underwriters' overallotment option to purchase up to 15% of additional shares. Actual size, price and other terms not yet determined by the company. Earlier (Mar....

JERSEY CITY, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data from its ongoing Phase 3 FU...